Search Results - "Vranckx, P"

Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium by LEON, Martin B, PIAZZA, Nicoto, MOREL, Marie-Angèle, PETERSEN, John, POPMA, Jeffrey J, TAKKENBERG, Johanna J. M, VAHANIAN, Alec, VAN ES, Gerrit-Anne, VRANCKX, Pascal, WEBB, John G, WINDECKER, Stephan, SERRUYS, Patrick W, NIKOLSKY, Eugenia, BLACKSTONE, Eugene H, CUTLIP, Donald E, PIETER KAPPETEIN, Arie, KRUCOFF, Mitchell W, MACK, Michael, MEHRAN, Roxana, MILLER, Craig

“…To propose standardized consensus definitions for important clinical endpoints in transcatheter aortic valve implantation (TAVI), investigations in an effort…”
Get full text

Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial by Costa, Francesco, Vranckx, Pascal, Leonardi, Sergio, Moscarella, Elisabetta, Ando, Giuseppe, Calabro, Paolo, Oreto, Giuseppe, Zijlstra, Felix, Valgimigli, Marco

“…We investigated if acute coronary syndrome (ACS) rather than stable coronary artery disease (SCAD) presentation is an outcome modifier with respect to the…”
Get full text

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) by Valgimigli, Marco, Borghesi, Marco, Tebaldi, Matteo, Vranckx, Pascal, Parrinello, Giovanni, Ferrari, Roberto

“…The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to…”
Get full text

Effects of pre‐hospital clopidogrel administration on early and late residual platelet reactivity in ST‐segment elevation myocardial infarction patients undergoing primary intervention by BISCAGLIA, S., TEBALDI, M., VRANCKX, P., CAMPO, G., VALGIMIGLI, M.

Get full text

Clinical development of bivalirudin (Angiox): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes by Serruys, P W, Vranckx, P, Allikmets, K

“…As the pathophysiology of acute coronary syndromes (ACS) has been clarified in recent years, major advances have been made in the management of the disease…”
Get more information

Doporučení ESC pro léčbu akutních koronárních syndromů 2023 by RA, Byrne, Rossello, X, JJ, Coughlan, Barbato, E, Berry, C, Chieffo, A, MJ, Claeys, GA, Dan, MR, Dweck, Galbraith, M, Gilard, M, Hinterbuchner, L, EA, Jankowska, Jüni, P, Kimura, T, Kunadian, V, Leosdottir, M, Lorusso, R, RFE, Pedretti, AG, Rigopoulos, Gimenez, Rubini M, Thiele, H, Vranckx, P, Wassmann, S, NK, Wenger, Ibanez, B, Kala, Petr, Ošťádal, Petr, Moťovská, Zuzana, Mates, Martin, Vondráková, Dagmar, Bělohlávek, Jan, Fila, Petr, Varvařovský, Ivo

Get full text

Femoral bifurcation infected pseudoaneurysm: a simple and quick arterial reconstruction with reversed bifurcated saphenous vein graft by Scavee, V, Vranckx, P, Pauls, C, Donnay, M, Heymans, M, Van Der Elst, P

“…Septic endarteritis complicating arterial cannulation is an exceptional condition. The authors report a quick and feasible surgical procedure to reconstruct a…”
Get more information

2018 ESC/EACTS Guidelines onmyocardial revascularization (vol 40, pg 87, 2019) by Neumann, FJ, Sousa-Uva, M, Ahlsson, A, Alfonso, F, Banning, AP, Benedetto, U, Byrne, RA, Collet, JP, Falk, V, Head, SJ

Get full text

LB004-MON NEUROMUSCULAR ELECTRICAL STIMULATION INCREASES SKELETAL MUSCLE PROTEIN SYNTHESIS RATES IN ELDERLY, TYPE 2 DIABETIC MEN by Kouw, I.W.K, Wall, B.T, Dirks, M.L, Verdijk, L.B, Snijders, T, Hansen, D, Vranckx, P, Burd, N.A, Senden, J, Dendale, P, van Loon, L.J

Get full text

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes by Valgimigli, Marco, Frigoli, Enrico, Leonardi, Sergio, Rothenbühler, Martina, Gagnor, Andrea, Calabrò, Paolo, Garducci, Stefano, Rubartelli, Paolo, Briguori, Carlo, Andò, Giuseppe, Repetto, Alessandra, Limbruno, Ugo, Garbo, Roberto, Sganzerla, Paolo, Russo, Filippo, Lupi, Alessandro, Cortese, Bernardo, Ausiello, Arturo, Ierna, Salvatore, Esposito, Giovanni, Presbitero, Patrizia, Santarelli, Andrea, Sardella, Gennaro, Varbella, Ferdinando, Tresoldi, Simone, de Cesare, Nicoletta, Rigattieri, Stefano, Zingarelli, Antonio, Tosi, Paolo, van ’t Hof, Arnoud, Boccuzzi, Giacomo, Omerovic, Elmir, Sabaté, Manel, Heg, Dik, Jüni, Peter, Vranckx, Pascal

“…In 7213 patients with an acute coronary syndrome, the rate of major adverse cardiovascular events was not significantly lower with bivalirudin than with…”
Get full text

European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: insights from an international survey by Van Edom, C, Castelein, T, Gramegna, M, Huber, K, Leonardi, S, Mueller, T, Pappalardo, F, Price, S, Schaubroeck, H, Schrage, B, Swol, J, Tavazzi, G, Vercaemst, L, Vranckx, P, Vandenbriele, C

“…Abstract Background Bleeding and thrombotic complications remain a major concern in cardiogenic shock (CS) patients undergoing percutaneous mechanical…”
Get full text

Edoxaban in atrial fibrillation with PCI by ACS or stable CAD presentation: a pre-specified analysis of the ENTRUST-AF PCI trial by Vranckx, P, Valgimigli, M, Eckardt, L, Lewalter, T, Laeis, P, Reimitz, P.E, Smolnik, R, Zierhut, W, Tijssen, J, Goette, A

“…Abstract Aim We aimed to compare the safety and efficacy of edoxaban in combination with P2Y12 inhibition in the setting of percutaneous coronary intervention…”
Get full text

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2) by Kappetein, Arie Pieter, Head, Stuart J., Généreux, Philippe, Piazza, Nicolo, van Mieghem, Nicolas M., Blackstone, Eugene H., Brott, Thomas G., Cohen, David J., Cutlip, Donald E., van Es, Gerrit-Anne, Hahn, Rebecca T., Kirtane, Ajay J., Krucoff, Mitchell W., Kodali, Susheel, Mack, Michael J., Mehran, Roxana, Rodés-Cabau, Josep, Vranckx, Pascal, Webb, John G., Windecker, Stephan, Serruys, Patrick W., Leon, Martin B.

“…OBJECTIVES The aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic…”
Get full text

P1952Value of GRACE risk score in risk stratification in acute coronary syndrome patients undergoing PCI in the Global Leaders study by Komiyama, H, Chichareon, P, Hamm, C, Juni, P, Valgimigli, M, Vranckx, P, Windecker, S, Onuma, Y, Stegg, G, Serruys, P

“…Abstract Aims We sought to evaluate the value of GRACE risk score in stratifying acute coronary syndrome patients undergoing percutaneous coronary intervention…”
Get full text

Efficacy and safety of early aspirin withdrawal and continuation of ticagrelor monotherapy post PCI for STEMI. A post hoc analysis of the randomized global leaders trial by Gamal Setih, A, Hara, H, Tomaniak, M, Lunardi, M, Gao, C, Ono, M, Kawashima, H, Juni, P, Vranckx, P, Windecker, S, Hamm, C, Gabriel Steg, P, Onuma, Y, Serruys, P

“…Abstract Background Clinical presentation with STEMI is considered as a highly prothrombotic condition often associated with recurrent ischemic events. The…”
Get full text

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy by Crea, Filippo

Get full text

P6408Potential benefit of ticagrelor monotherapy for patients with hypertension undergoing percutaneous coronary intervention: insights from the Global Leaders trial by Modolo, R, Chichareon, P, De Faria, A P, Steg, P G, Hamm, C, Vranckx, P, Valgimigli, M, Windecker, S, Onuma, Y, Serruys, P W

“…Abstract Background Hypertension is one of the most frequent modifiable risk factors for coronary artery disease. Due to the increased risk of bleeding…”
Get full text

Ticagrelor monotherapy beyond 1 month versus standard dual antiplatelet therapy after drug-eluting coronary stenting: a pre-specified per-protocol analysis of the GLOBAL LEADERS trial by Gragnano, F, Zwahlen, M, Vranckx, P, Juni, P, Heg, D, Hamm, C, Steg, P.G, Hagenbuch, N, Gargiulo, G, Van Geuns, R.J, Huber, K, Van Amsterdam, R, Serruys, P.W, Valgimigli, M, Windecker, S

“…Abstract Background In the GLOBAL LEADERS trial, the intention-to-treat (ITT) effect of ticagrelor monotherapy after 1 month of dual antiplatelet therapy…”
Get full text

Systemic embolism during coronary artery bypass surgery by VRANCKX, P, VAN DYCK, M, DUDEKEM, Y

Get full text

Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study by VALGIMIGLI, Marco, CAMPO, Gianluca, COLANGELO, Salvatore, BRUGALETTA, Salvatore, PARRINELLO, Giovanni, PERCOCO, Gianfranco, FERRARI, Roberto, DE CESARE, Nicoletta, MELIGA, Emanuele, VRANCKX, Pascal, FURGIERI, Alessandro, ANGIOLILLO, Dominick J, SABATE, Manel, HAMON, Martial, REPETTO, Alessandra

“…Inhibition of platelet aggregation after aspirin or clopidogrel intake varies greatly among patients, and previous studies have suggested that poor response to…”
Get full text